Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 3, 2016

View Archived Issues

BioLineRx in-licenses liver fibrosis drug candidate

Novartis patents angiotensin receptor antagonists

University of Occupational and Environmental Health and Yakult Honsha disclose ZNF143 inhibitors

Evelo Biosciences, Mayo Clinic to collaborate on immuno-microbiome-based therapies for cancer

Pivotal phase III ATLANTIS study of PharmaMar's lurbinectedin begins

FDA grants orphan drug designation to Agilis Biotherapeutics' AGIL-FA

REGENXBIO's RGX-121 wins FDA rare pediatric disease designation

Divestiture of Allergan's generic business to Teva complete

Long-term safety of CERE-120 in patients with Parkinson's disease

Meda shareholders accept Mylan offer

Regeneron and Adicet Bio enter collaboration to develop next-generation immune cell therapeutics

ContraVir Pharmaceuticals' tenofovir analogue for HBV safe and well tolerated in phase Ib study

Daiichi Sankyo profiles pipeline progress of first quarter of fiscal 2016

AbbVie reports key events from second quarter 2016

GeoVax awarded contract from NIH to further develop HIV vaccine

BARDA awards contract to Altimmune for anthrax vaccine candidate

Abeona Therapeutics gives update on phase I/II study of MPS IIIA treatment

HTIT makes milestone payment to Oramed for oral insulin product

Shionogi transfers 21 long-listed drugs to Lupin's subsidiary Kyowa in Japan

Novartis' LEE-011 receives FDA breakthrough therapy designation

Keytruda approved in Europe for patients with advanced NSCLC whose tumors express PD-L1

Human commensals found to produce a novel antibiotic

CDC Zika MAC-ELISA test now available to commercial laboratories

Activity of secukinumab on brain lesions in RRMS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...